ClinicalTrials.gg
Active, not recruitingNCT06212999STOP-HS LTEUpdated Aug 25, 2026

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3 interventional study of Povorcitinib in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation. Active, not recruiting at 165 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
2nd of 12
617 · median 391
Started
2024
the only one that year
Phase 3
6 of 12
1 open now
Registered
7th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 2nd largest by enrollment, is the only one that started in 2024, is one of 6 in phase 3, and was the 7th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • Hidradenitis Suppurativa
  • Hidradenitis
  • Acne inversa
  • HS
  • Povorcitinib
  • Long-Term Extension (LTE)
  • INCB054707
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302).
  • Agreement to use .
  • Willing and able to comply with the study protocol and procedures.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Participation in the extension study could expose the participant to an undue safety risk.
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Cohort A

    Povorcitinib at the protocol-defined dose strength based on cohort assignment.

    Drug: Povorcitinib

  • Experimental
    Cohort B

    Povorcitinib at the protocol-defined dose strength based on cohort assignment.

    Drug: Povorcitinib

  • Experimental
    Cohort C

    Povorcitinib at the protocol-defined dose strength based on cohort assignment.

    Drug: Povorcitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)

    TEAE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.

    Time frame: up to approximately 56 weeks

Secondary outcomes

  1. Proportion of participants with Serious Treatment-Emergent Adverse Events (TEAEs)

    Serious TEAE is defined as any untoward medical occurrence that, at any dose, meet at least one of the following criteria: (a) results in death; (b) is life-threatening; (c) requires inpatient hospitalization or prolongation of existing hospitalization; (d) results in persistent or significant disability/incapacity; (e) is a congenital anomaly/birth defect; (f) is an important medical event.

    Time frame: up to approximately 56 weeks

  2. Proportion of participants with TEAEs leading to study drug discontinuation

    Defined as any TEAE that leads to discontinuation of study drug.

    Time frame: up to approximately 56 weeks

  3. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)

    HiSCR is defined as at least a 50% reduction from baseline of parent study in the total abscess and inflammatory nodule (AN) count, with no increase from baseline of parent study in abscess or draining tunnel count.

    Time frame: up to approximately 56 weeks

  4. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)

    HiSCR75 is defined as at least a 75% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.

    Time frame: up to approximately 56 weeks

  5. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 90 (HiSCR90)

    HiSCR90 is defined as at least a 90% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.

    Time frame: up to approximately 56 weeks

  6. Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 100 (HiSCR100)

    HiSCR100 is defined as a 100% reduction from baseline of parent study in the total AN count, with no increase from baseline of parent study in abscess or draining tunnel count.

    Time frame: up to approximately 56 weeks

  7. Proportion of participants with flare at each visit

    Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 ANs relative to Week 54.

    Time frame: up to approximately 56 weeks

  8. Time to first flare

    Time to first flare during the long-term extension study.

    Time frame: up to approximately 56 weeks

  9. Mean change from baseline of parent study in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each visit

    The HiSQoL is a HS-specific, health-related quality of life (QoL) instrument. The HiSQoL total score ranges from 0 to 68, with higher scores indicating higher disease impact on QoL.

    Time frame: up to approximately 56 weeks

  10. Mean change from baseline of parent study in Dermatology Life Quality Index (DLQI) score at each visit

    The DLQI is a skin disease specific questionnaire aimed at the evaluation of how symptoms and treatment affect participants' health-related quality of life (QoL). The DLQI total score ranges from 0 to 30, with higher scores indicating lower skin health related QoL.

    Time frame: up to approximately 56 weeks

  11. Proportion of participants with no increase in abscess and inflammatory nodule (AN) count relative to Week 54 at each visit

    Time frame: up to approximately 56 weeks

  12. Proportion of participants with no increase in abscess, inflammatory nodule, and draining tunnel (ANdT) count relative to Week 54 at each visit

    ANdT count is defined as the total sum of abscesses, inflammatory nodules, and draining tunnels.

    Time frame: up to approximately 56 weeks

  13. Proportion of participants with no increase in draining tunnel count relative to Week 54 at each visit

    Time frame: up to approximately 56 weeks

  14. Proportion of participants with a total AN count of 0, 1, or 2 at each visit

    AN count defined as the total sum of abscesses and inflammatory nodules.

    Time frame: up to approximately 56 weeks

  15. Proportion of participants with a total ANdT count of 0, 1, or 2 at each visit

    ANdT count is defined as the total sum of abscesses, inflammatory nodules, and draining tunnels.

    Time frame: up to approximately 56 weeks

07

Study locations

165 sites
  • Investigative Site US303
    Phoenix, Arizona 85006, United States
  • Investigative Site US240
    Scottsdale, Arizona 85255, United States
  • Investigative Site US307
    Fort Smith, Arkansas 72916, United States
  • Investigative Site US214
    Rogers, Arkansas 72758, United States
  • Investigative Site US315
    Laguna Niguel, California 92677, United States
  • Investigative Site US223
    Los Angeles, California 90033, United States
  • Investigative Site US222
    Oakland, California 94611, United States
  • Investigative Site US226
    San Diego, California 92103, United States
  • Investigative Site US309
    Clearwater, Florida 33614, United States
  • Investigative Site US317
    Hialeah, Florida 33012-3618, United States
  • Investigative Site US306
    Hollywood, Florida 33021, United States
  • Investigative Site US320
    Hollywood, Florida 33021, United States
  • Investigative Site US316
    Maitland, Florida 32751, United States
  • Investigative Site US227
    Margate, Florida 33063, United States
  • Investigative Site US204
    Miami, Florida 33125, United States
  • Investigative Site US236
    Miami, Florida 33173, United States
  • Investigative Site US321
    North Miami Beach, Florida 33162-4708, United States
  • Investigative Site US200
    Ocala, Florida 34470, United States
  • Investigative Site US228
    Tampa, Florida 33609, United States
  • Investigative Site US201
    Tampa, Florida 33613, United States
  • Investigative Site US311
    Marietta, Georgia 30060, United States
  • Investigative Site US220
    West Dundee, Illinois 60118, United States
  • Investigative Site US206
    Indianapolis, Indiana 46250, United States
  • Investigative Site US337
    Indianapolis, Indiana 46250, United States
  • Investigative Site US341
    Bowling Green, Kentucky 42104, United States
  • Investigative Site US209
    Louisville, Kentucky 40241, United States
  • Investigative Site US305
    Baton Rouge, Louisiana 70809, United States
  • Investigative Site US207
    Metairie, Louisiana 70006, United States
  • Investigative Site US229
    New Orleans, Louisiana 70115, United States
  • Investigative Site US224
    Baltimore, Maryland 21287, United States
  • Investigative Site US325
    Marriottsville, Maryland 21104, United States
  • Investigative Site US225
    Boston, Massachusetts 02115, United States
  • Investigative Site US304
    Boston, Massachusetts 02215, United States
  • Investigative Site US310
    Brighton, Massachusetts 02135, United States
  • Investigative Site US221
    Quincy, Massachusetts 02169, United States
  • Investigative Site US213
    Fort Gratiot, Michigan 48059, United States
  • Investigative Site US217
    Waterford, Michigan 48328, United States
  • Investigative Site US212
    Minneapolis, Minnesota 55455, United States
  • Investigative Site US302
    St Louis, Missouri 63110, United States
  • Investigative Site US318
    Portsmouth, New Hampshire 03801, United States
  • Investigative Site US230
    East Windsor, New Jersey 08520, United States
  • Investigative Site US324
    Kew Gardens, New York 11415, United States
  • Investigative Site US202
    New York, New York 10028, United States
  • Investigative Site US210
    Rochester, New York 14620, United States
  • Investigative Site US205
    Chapel Hill, North Carolina 27516, United States
  • Investigative Site US215
    Bexley, Ohio 43209, United States
  • Investigative Site US339
    Bexley, Ohio 43209, United States
  • Investigative Site US330
    Boardman, Ohio 44512, United States
  • Investigative Site US314
    Cincinnati, Ohio 45219, United States
  • Investigative Site US312
    Cleveland, Ohio 44106, United States
  • Investigative Site US203
    Gahanna, Ohio 43230, United States
  • Investigative Site US301
    Portland, Oregon 97201, United States
  • Investigative Site US232
    Murfreesboro, Tennessee 37130, United States
  • Investigative Site US235
    Arlington, Texas 76011, United States
  • Investigative Site US218
    Bellaire, Texas 77401, United States
  • Investigative Site US340
    Bellaire, Texas 77401, United States
  • Investigative Site US238
    Pflugerville, Texas 78660, United States
  • Investigative Site US300
    Plano, Texas 75025, United States
  • Investigative Site US234
    San Antonio, Texas 78213, United States
  • Investigative Site US313
    Norfolk, Virginia 23502, United States
  • Investigative Site US308
    Spokane, Washington 99202, United States
  • Investigative Site AU203
    Charlestown, New South Wales 02290, Australia
  • Investigative Site AU205
    Kogarah, New South Wales 02217, Australia
  • Investigative Site AU200
    Liverpool, New South Wales 02170, Australia
  • Investigative Site AU206
    Woolloongabba, Queensland 04102, Australia
  • Investigative Site AU207
    Woolloongabba, Queensland 04102, Australia
  • Investigative Site AU201
    Carlton, Victoria 03053, Australia
  • Investigative Site AU204
    Melbourne, Victoria 03002, Australia
  • Investigative Site AT306
    Inssbruck, 06020, Austria
  • Investigative Site AT305
    Vienna, 01090, Austria
  • Investigative Site BE300
    Brussels, 01070, Belgium
  • Investigative Site BE301
    Ghent, 09000, Belgium
  • Investigative Site BE302
    Liège, 04000, Belgium
  • Investigative Site BG203
    Sofia, 01407, Bulgaria
  • Investigative Site BG202
    Sofia, 01463, Bulgaria
  • Investigative Site BG200
    Sofia, 01510, Bulgaria
  • Investigative Site BG204
    Sofia, 01606, Bulgaria
  • Investigative Site BG201
    Stara Zagora, 06000, Bulgaria
  • Investigative Site CA202
    Calgary, Alberta T3E 0B2, Canada
  • Investigative Site CA204
    Edmonton, Alberta T6G 1C3, Canada
  • Investigative Site CA200
    Surrey, British Columbia V3V 0C6, Canada
  • Investigative Site CA301
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigative Site CA205
    Fredericton, New Brunswick E3B 1G9, Canada
  • Investigative Site CA304
    Barrie, Ontario L4M 7G1, Canada
  • Investigative Site CA308
    Hamilton, Ontario L8L 3C3, Canada
  • Investigative Site CA303
    London, Ontario N6H 5L5, Canada
  • Investigative Site CA207
    Mississauga, Ontario L4W 0C2, Canada
  • Investigative Site CA302
    Peterborough, Ontario K9J 5K2, Canada
  • Investigative Site CA208
    Richmond Hill, Ontario L4B 1L1, Canada
  • Investigative Site CA307
    Montreal, Quebec H2X 2V1, Canada
  • Investigative Site CA206
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Investigative Site CA203
    St. John's, A1A 4Y3, Canada
  • Investigative Site CZ301
    Ostrava - Poruba, 708 52, Czechia
  • Investigative Site CZ300
    Prague, 150 06, Czechia
  • Investigative Site DK200
    Århus N, 08200, Denmark
  • Investigative Site DK201
    Roskilde, 04000, Denmark
  • Investigative Site FR305
    Bordeaux, 33000, France
  • Investigative Site FR303
    Brest, 29609, France
  • Investigative Site FR205
    Dijon, 21000, France
  • Investigative Site FR307
    Le Mans, 72037, France

Showing the first 100 of 165 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 34 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Jan 30, 2024
Primary completionEst.
Dec 26, 2026
CompletionEst.
Dec 26, 2026
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06212999
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Jan 30, 2024
Primary completion
Dec 26, 2026 (estimated)
Completion
Dec 26, 2026 (estimated)
Last update
Aug 25, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion